CurrentBlue Cross Blue Shield - Rhode IslandPolicy N/A

Peanut (Arachis hypogaea) Allergen Powder-dnfp (Palforzia) coverage

This medical policy governs coverage determination for peanut (Arachis hypogaea) allergen powder-dnfp (oral immunotherapy / Palforzia) for commercial and Medicare Advantage populations under Blue Cross Blue Shield - Rhode Island. It states the plan’s coverage stance, diagnostic context, treatment background, and billing guidance.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyPeanut (Arachis hypogaea) Allergen Powder-dnfp (Palforzia) coverage

Policy CodePolicy N/A

Change TypeClarified: not covered / not medically necessary

Effective DateApr 1, 2021

Next Review Date

Key ActionDo not expect benefit coverage for peanut (Arachis hypogaea) allergen powder-dnfp; document that the product is considered not medically necessary per policy if submitted for reimbursement.

SourceLink

POLICY UPDATE CHANGES

Policy states peanut allergen powder-dnfp is not covered / not medically necessary due to insufficient evidence.

1Primary coverage stance (not covered)

555Pivotal trial randomized participants (4-55 yrs)

67.2% vs 4.0%Primary endpoint (tolerating >=600 mg)

14.2%Systemic allergic reactions in treated arm

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Summary

This policy governs coverage determination for peanut (Arachis hypogaea) allergen powder-dnfp (oral immunotherapy / Palforzia) for commercial and Medicare Advantage populations under Blue Cross Blue Shield - Rhode Island. The plan's stance is not covered / not medically necessary. Peanut allergy is common in children and standard of care is strict avoidance with prompt treatment of reactions; a pivotal randomized trial (n=555 randomized, subset n=499 ages 4–17 for primary analysis) found that 67.2% vs 4.0% met the primary endpoint of tolerating ≥600 mg peanut protein (difference 63.2%, 95% CI 53.0 to 73.3, p<0.001).

Key Policy Facts

Effective Date04/01/2021

Last Review02/03/2021

Policy StatusCURRENT

Coverage StanceNot covered / Not medically necessary (evidence insufficient)

Medical Necessity / Coverage Determination

Policy Statement

Coverage determination for peanut (Arachis hypogaea) allergen powder-dnfp:

Not covered / Not medically necessary: Use of peanut (Arachis hypogaea) allergen powder-dnfp is considered not covered / not medically necessary because the evidence is insufficient to determine the effects of the technology on health outcomes.
Applies to commercial products; benefits vary by contract per Coverage section.

Diagnosis (context / clinical notes)

Information on diagnostic approach (not coverage criteria):

Diagnostic context

Clinical diagnosis: Diagnosis of peanut allergy is based on an unequivocal history of immediate allergic reaction following peanut ingestion and may use skin prick testing and peanut-specific IgE levels to establish post-test probability.
Oral food challenge: Double-blind, placebo-controlled oral food challenges are the diagnostic gold standard but are not routinely performed due to risk of severe reactions; they may be required if history and IgE results are unclear.

Not Medically Necessary / Not Covered

The policy concludes that peanut allergen powder-dnfp (Palforzia) is considered not medically necessary / not covered because the evidence is insufficient to determine effects on health outcomes. The evidence summary notes limitations including unclear intended-use population, short duration, potential for unblinding, and that desensitization has not been shown to reduce reactions to accidental exposure or to improve quality of life.

Provider Actions / Billing Guidance

Documentation Required

Coverage determination for Palforzia

Do not expect benefit coverage for peanut (Arachis hypogaea) allergen powder-dnfp (Palforzia). If submitted for reimbursement, document that the product is considered not medically necessary per policy.

J8499

Billing Rule

Use unlisted HCPCS for claims

Claims for Palforzia should be filed using the unlisted HCPCS code J8499 because there is no specific CPT code for this treatment.

J8499
No specific CPT code exists for Palforzia

Background & Evidence Summary

Peanut allergy is typically managed with strict avoidance of peanut-containing foods and prompt treatment (epinephrine, antihistamines, steroids) for reactions. Oral immunotherapy (OIT) using peanut allergen powder-dnfp has been studied in trials and practiced in some centers or clinics, but studies vary in formulations, dosing strategies, maintenance doses, and target populations. Trials report higher frequency and severity of adverse events with peanut allergen powder-dnfp versus placebo (including systemic allergic reactions, increased epinephrine use outside challenge, and higher withdrawal rates), and available evidence is considered inadequate to demonstrate improved long-term health outcomes or safety.

Label	Value
Pivotal randomized trial - primary outcome
67.2% vs 4.0% met primary endpoint (tolerate >=600 mg) in treated vs placebo; difference 63.2% (95% CI 53.0 to 73.3), p<0.001
Serious adverse events
Higher in treated arm (e.g., systemic allergic reactions 14.2% vs 3.2%; epinephrine use outside challenge 14.0% vs 6.5%; withdrawal due to AEs 11.6% vs 2.4%)
Evidence conclusion
Insufficient to determine effects on health outcomes; limitations include unclear intended-use population, short duration, and potential unblinding.
Recommended billing code guidance
J8499: Prescription oral, non chemotherapeutic, NOS drug (unlisted HCPCS recommended for Palforzia)

Peanut (Arachis hypogaea) allergen powder-dnfp: a defatted, slightly roasted peanut flour with a characterized peanut allergen used for oral desensitization (Palforzia).